Given the recognized immunometabolic functions of adiponectin and its protective role against obesity development, reduced adiponectin levels are considered unfavorable and constitute risk factors for diabetes and metabolic syndrome. This evidence concerns the gene ADIPOQ and metabolic syndrome.